Bosutinib – 100 mg

Brand:
Cayman
CAS:
380843-75-4
Storage:
-20
UN-No:
Non-Hazardous - /

Bosutinib is an inhibitor of c-Src and Abl kinases (IC50s = 1.2 and 1 nM, respectively).{22602,22595} It also inhibits the kinases EPHB2, TrkA, TrkB, and TXK (IC50s = 8.5, 22, 27, and 40 nM, respectively) among others.{22603} Bosutinib inhibits Src-dependent cell proliferation (IC50 = 100 nM) and reverses Src-transformed fibroblasts to a non-transformed morphology when used at a concentration of 1 µM.{22602} It reduces tumor growth in unstaged and staged Src-transformed fibroblast mouse xenograft models when administered at doses of 30 or 25 mg/kg, respectively, twice per day. Bosutinib (100 mg/kg) also induces complete tumor regression in a K562 mouse xenograft model when administered once per day for five days.{22595}  

 

Available on backorder

SKU: 12030 - 100 mg Category:

Description

An inhibitor of c-Src and Abl kinases (IC50s = 1.2 and 1 nM, respectively); inhibits the kinases EPHB2, TrkA, TrkB, and TXK (IC50s = 8.5, 22, 27, and 40 nM, respectively) among others; inhibits Src-dependent cell proliferation (IC50 = 100 nM); reduces tumor growth in unstaged and staged Src-transformed fibroblast mouse xenograft models at 30 or 25 mg/kg, respectively, twice per day; induces complete tumor regression in a K562 mouse xenograft model at 100 mg/kg once per day for five days


Formal name: 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile

Synonyms:  SKI 606

Molecular weight: 530.5

CAS: 380843-75-4

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Kinase Inhibitors|Abl Family & Bcr-Abl||Product Type|Biochemicals|Kinase Inhibitors|SRC Family||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Signaling|Abl family & Bcr-Abl Signaling||Research Area|Cancer|Cell Signaling|SRC Family Signaling